Two-year outcomes of "treat and extend" intravitreal therapy for neovascular age-related macular degeneration

Ophthalmology

Volumn 122, Issue 6, 2015, Pages 1212-1219

  Arnold, Jennifer J ^a   Campain, Anna ^a   Barthelmes, Daniel ^b,c   Simpson, Judy M ^d   Guymer, Robyn H ^e   Hunyor, Alex P ^b,f   McAllister, Ian L ^g   Essex, Rohan W ^h   Morlet, Nigel ^g   Gillies, Mark C ^a  

^a Marsden Eye Specialists   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d UNIVERSITY OF SYDNEY   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f Chatswood Eye Specialists   (Australia)

^g UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^h AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; BLEEDING; CLINICAL PRACTICE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; ENDOPHTHALMITIS; EYE SURGERY; FEMALE; FOLLOW UP; HUMAN; INFECTIOUS ENDOPHTHALMITIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; QUALITY CONTROL; READING; RETINA DETACHMENT; SUBRETINAL NEOVASCULARIZATION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; INTRAVITREAL DRUG ADMINISTRATION; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; REGISTER; VERY ELDERLY; WET MACULAR DEGENERATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MALE; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; REGISTRIES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84930041344     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2015.02.009     Document Type: Article

References (25)

1. P.J. Rosenfeld, D.M. Brown, J.S. Heier MARINA Study Group Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 2006 1419 1431
2. D.M. Brown, P.K. Kaiser, M. Michels ANCHOR Study Group Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 2006 1432 1444
3. J.S. Heier, D.M. Brown, and V. Chong Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration Ophthalmology 120 2012 209 210
4. CATT Research Group, D.F. Martin, and M.G. Maguire Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results Ophthalmology 119 2012 1388 1398
5. CATT Research Group, D.F. Martin, and M.G. Maguire Ranibizumab and bevacizumab for neovascular age-related macular degeneration N Engl J Med 364 2011 1897 1908
6. B.G. Busbee, A.C. Ho, and D.M. Brown Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration Ophthalmology 120 2013 1046 1056
7. A.C. Ho, B.G. Busbee, and C.D. Regillo Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration Ophthalmology 121 2014 2181 2192
8. T.W. Stone ASRS 2014 Preferences and Trends Membership Survey 2014 American Society of Retina Specialists Chicago
9. K. Berg, T.R. Pedersen, L. Sandvik, and R. Bragadóttir Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol Ophthalmology 122 2015 146 152
10. H. Oubraham, S.Y. Cohen, and S. Samimi Inject and extend dosing versus dosing as needed: a comparative retrospective study of ranibizumab in exudative age-related macular degeneration Retina 31 2011 26 30
11. O.P. Gupta, G. Shienbaum, and A.H. Patel A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact Ophthalmology 117 2010 2134 2140
12. N. Toalster, M. Russell, and P.A. Ng 12-month prospective trial of inject and extend regimen for ranibizumab treatment of age-related macular degeneration Retina 33 2013 1351 1358
13. G. Shienbaum, O.P. Gupta, and C. Fecarotta Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: clinical and economic impact Am J Ophthalmol 153 2012 468 473
14. R. Spaide Ranibizumab according to need: a treatment for age-related macular degeneration Am J Ophthalmol 143 2007 679 680
15. F. Abedi, S. Wickremasinghe, and A.F. Islam Anti-VEGF treatment in neovascular age-related macular degeneration: a treat-and-extend protocol over 2 years Retina 34 2014 1531 1538
16. M.C. Gillies, J. Liong, and R. Walton Efficient capture of high-quality data on outcomes of treatment for macular diseases: the Fight Retinal Blindness! Project Retina 34 2013 188 195
17. R Development Core Team R: A Language and Environment for Statistical Computing 2012 R Foundation for Statistical Computing Vienna, Austria
18. W.S. Cleveland, E. Grosse, and W.M. Shyu Local regression models. Statistical Models in S 1992 Wadsworth & Brooks/Cole New York
19. M.C. Gillies, R. Walton, and J.M. Simpson Prospective audit of exudative age-related macular degeneration: 12-month outcomes in treatment-naive eyes Invest Ophthalmol Vis Sci 54 2013 5754 5760
20. Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity Ophthalmology 121 2014 1092 1101
21. P.S. Muether, M.M. Hermann, and K. Dröge Long-term stability of vascular endothelial growth factor suppression time under ranibizumab treatment in age-related macular degeneration Am J Ophthalmol 156 2013 989 993
22. G.A. Lalwani, P.J. Rosenfeld, and A.E. Fung A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study Am J Ophthalmol 148 2009 43 58.e1
23. J.S. Heier, D.M. Brown, and V. Chong Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration Ophthalmology 119 2012 2537 2548
24. A. Vaze, S. Fraser-Bell, and M.C. Gillies Reasons for discontinuation of intravitreal vascular endothelial growth factor inhibitors in neovascular age-related macular degeneration Retina 34 2004 1774 1778
25. M.C. Gillies, A. Campain, and R. Walton Time to initial clinician-reported inactivation of neovascular age-related macular degeneration treated primarily with ranibizumab Ophthalmology 122 2015 589 594.e1